IMPACT OF THE MYCOCARE PATIENT SUPPORT PROGRAM ON THE MANAGEMENT OF PATIENTS WITH PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS
Author(s)
Camille Legghe, PharmD, PhD1, Sophie Gauthier, PhD1, Vincent Dubee, MD, PhD2, Geneviève Hery-Arnaud, MD, PhD3, Laure Danièle, MSc4, Nathanael SEDMAK, MSc5, Christian Dupont, BSc6, Benoit Falquet, MD7, Thomas Maitre, MD, PhD8, Raphael Chiron, MD9.
1Patientys by Concentrix, Boulogne-Billancourt, France, 2Departments of Infectious Diseases, Angers University Hospital, Angers, France, 3Department of Infectious Agents, Bacteriology Laboratory, Brest University Hospital, Brest, France, 4Department of Pulmonology, Nice University Hospital, Nice, France, 5RCTs, Lyon, France, 6Department of Pulmonology, Cochin University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France, 7Department of Pharmacy, Hôpitaux Nord-Ouest, Villefranche-sur-Saône, France, 8Department of Pulmonology and Thoracic Oncology, National Reference Center for Rare Lung Disease, APHP Hôpital Tenon and Sorbonne Université and Cimi Paris, Inserm U1135, Paris, France, 9Cystic Fibrosis Center, Montpellier University Hospital, Montpellier, France.
1Patientys by Concentrix, Boulogne-Billancourt, France, 2Departments of Infectious Diseases, Angers University Hospital, Angers, France, 3Department of Infectious Agents, Bacteriology Laboratory, Brest University Hospital, Brest, France, 4Department of Pulmonology, Nice University Hospital, Nice, France, 5RCTs, Lyon, France, 6Department of Pulmonology, Cochin University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France, 7Department of Pharmacy, Hôpitaux Nord-Ouest, Villefranche-sur-Saône, France, 8Department of Pulmonology and Thoracic Oncology, National Reference Center for Rare Lung Disease, APHP Hôpital Tenon and Sorbonne Université and Cimi Paris, Inserm U1135, Paris, France, 9Cystic Fibrosis Center, Montpellier University Hospital, Montpellier, France.
OBJECTIVES: Pulmonary non-tuberculous mycobacterial infections (NTM-PD) require complex and prolonged antibiotic treatment regimens. However, treatment-related adverse events (AEs) are a major contributor to poor adherence. The MYCOCARE patient support program was developed to assist patients with NTM-PD and improve their care pathway. This study aimed to assess the impact of MYCOCARE on treatment tolerance, adherence, and quality of life.
METHODS: A retrospective analysis was conducted using data collected through follow-up telephone calls and patient self-administered questionnaires. Treatment adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment tolerance and quality of life were evaluated using reported adverse events and the EQ-5D-3L questionnaire, respectively.
RESULTS: A total of 160 patients were enrolled in the MYCOCARE program, of whom 59 (36.9%) discontinued treatment during follow-up. The proportion of patients reporting at least one adverse event decreased over time, from 90.0% at baseline to 33.3% at Month 12. Among patients who discontinued participation in the program, adverse events led to treatment discontinuation in 12 cases (35.3%). At Month 12, 79.5% of patients demonstrated moderate or high adherence to treatment. Quality of life remained high and stable throughout follow-up, with no significant changes observed over time.
CONCLUSIONS: The MYCOCARE program may contribute to maintaining treatment adherence through improved management of treatment-related adverse events. More broadly, the program may enhance coordination among healthcare professionals involved in the management of NTM-PD, strengthen collaboration between hospital and community care settings, and improve patients' understanding of their disease and treatment.
METHODS: A retrospective analysis was conducted using data collected through follow-up telephone calls and patient self-administered questionnaires. Treatment adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Treatment tolerance and quality of life were evaluated using reported adverse events and the EQ-5D-3L questionnaire, respectively.
RESULTS: A total of 160 patients were enrolled in the MYCOCARE program, of whom 59 (36.9%) discontinued treatment during follow-up. The proportion of patients reporting at least one adverse event decreased over time, from 90.0% at baseline to 33.3% at Month 12. Among patients who discontinued participation in the program, adverse events led to treatment discontinuation in 12 cases (35.3%). At Month 12, 79.5% of patients demonstrated moderate or high adherence to treatment. Quality of life remained high and stable throughout follow-up, with no significant changes observed over time.
CONCLUSIONS: The MYCOCARE program may contribute to maintaining treatment adherence through improved management of treatment-related adverse events. More broadly, the program may enhance coordination among healthcare professionals involved in the management of NTM-PD, strengthen collaboration between hospital and community care settings, and improve patients' understanding of their disease and treatment.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR200
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)